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Background: Hyperglycemia in pregnancy is associated with poor perinatal outcome. Even if pregnant women
with diabetes are monitored according to current guidelines, they do much worse than their normoglycaemic
counterparts, marked by increased risks of pre-eclampsia, macrosomia, and caesarean section amongst others.
Continuous Glucose Monitoring (CGM) is a new method providing detailed information on daily fluctuations, used
to optimize glucose control. Whether this tool improves pregnancy outcome remains unclear. In the present
protocol, we aim to assess the effect of CGM use in diabetic pregnancies on pregnancy outcome.
Methods/design: The GlucoMOMS trial is a multicenter open label randomized clinical trial with a decision and
cost-effectiveness study alongside. Pregnant women aged 18 and over with either diabetes mellitus type 1 or 2 on
insulin therapy or with gestational diabetes requiring insulin therapy before 30 weeks of gestation will be asked to
participate. Consenting women will be randomly allocated to either usual care or complementary CGM. All women
will determine their glycaemic control by self-monitoring of blood glucose levels and HbA1c. In addition, women
allocated to CGM will use it for 5–7 days every six weeks. Based on their CGM profiles they receive dietary advice
and insulin therapy adjustments if necessary. The primary outcome measure is rate of macrosomia, defined as a
birth weight above the 90th centile. Secondary outcome measures will be birth weight, composite neonatal
morbidity, maternal outcome and costs. The analyses will be according to the intention to treat principle.
Discussion: With this trial we aim at clarifying whether the CGM improves pregnancy outcome when used during
diabetic pregnancies.
Trial registration: Nederlands Trial Register: NTR2996
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Diabetes during pregnancy is a high risk situation for both
mother and the child. Optimising glycaemic control is a
key feature of prenatal care for diabetic women [1]. Since
the 1960s, there has been a reduction in perinatal morbidity
and mortality [2,3]. However, even if pregnant women with
diabetes are monitored according to current guidelines,
they do much worse than their normoglycaemic counter-
parts. In a nationwide study in 2000 on the outcome of 323
women with a pregnancy complicated by type 1 diabetes* Correspondence: d.p.vanmunster-2@umcutrecht.nl
1Department of Obstetrics and Gynaecology, University Medical Centre
Utrecht, Utrecht, the Netherlands
Full list of author information is available at the end of the article
© 2012 Voormolen et al.; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumwe found a high prevalence of maternal, perinatal and
neonatal complications [4]. These complications occurred
despite good pre-pregnancy care, as 84% of these pregnan-
cies were planned and 70% used adequate folic acid sup-
plementation. Overall, glycaemic control during these
pregnancies was acceptable, as average HbA1c value was
44 mmol/mol. Nevertheless, these pregnancies showed
high complications rates that require improvement.
The continuous glucose monitoring system (CGMS) is
a new technique that retrospectively provides detailed
information regarding glucose fluctuations during the
day. The CGMS has been studied in non-pregnant
patients where it has demonstrated clinical usefulness by
enhancing decision-making through detecting previouslytral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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nal hyper-and hypoglycemia [5]. Scientific evidence on a
HbA1c-reducing effect of CGMS use is limited [6,7].
Although some studies do evaluate the effect of CGMS
use on biochemical endpoints, such as HbA1c levels,
data on clinical endpoints like diabetic complications,
are lacking. The usefulness of CGMS use during preg-
nancy has hardly been evaluated up to now [7]. A recent
RCT showed that intermittent CGMS use during preg-
nancy in 71 women with pre-existing diabetes resulted
in a significant reduction in HbA1c at 32–36 weeks ges-
tation. Furthermore, the odds ratio for reduced risk of
macrosomia was 0.36 (95% CI 0.13-0.98, p = 0.05) [8].
However, this study was hampered by small sample size
and both study groups differed in composition (e.g. 5 set
of twins in the intervention group as opposed to none in
the control group). Furthermore 11 (4%) of the children
in the intervention group were small for gestational age
(≤10 centile) as opposed to none in the control group.
This difference did not reach statistical significance
either but may point to an adverse effect of CGMS. An-
other recent RCT by Secher et al. investigated the effect
of intermittent real time CGMS use during pregnancy in
154 women with pre-existing diabetes on pregnancy
outcome [9]. The rate of macrosomia was not significantly
different between the intervention group (43%) and the
control group (30%) (p = 0.09). Also, HbA1c levels were
similar in both groups. The investigators concluded that
intermittent CGMS use did not improve glycaemic
control in pregnancy nor did it improve pregnancy
outcome. Thus, further evaluation in larger studies is
urgently needed before wide implementation of
CGMS during pregnancy.
Relevance
Despite improvements in blood glucose monitoring
technology, and obstetric and neonatal care over the last
decades, maternal and fetal complications occur much
more frequent in diabetic women than in non-diabetic
women [4]. Our Dutch nationwide study of type 1 dia-
betes mellitus in pregnancy showed high complication
rates in diabetes pregnancies. Maternal complications
were episodes of severe hypoglycemia (40%), pre-
eclampsia (13%) and caesarean section (44%). Perinatal
and neonatal complications included congenital malfor-
mations (9%), prematurity (32%), perinatal mortality
(3%), macrosomia (45%) and neonatal morbidity such as
shoulder dystocia (14%), all remarkably higher rates than
those in non-diabetic pregnancies [4]. Similar rates of
complications have recently been found in other na-
tionwide studies in Denmark, the United Kingdom
and Sweden [10-12]. In the Dutch study 45% of the
newborns were macrosomic and 24% were extremely
macrosomic (>p97.7). Recent data from Denmarkshow that 56% of the newborns of type 2 diabetic
women were macrosomic [11].
The prevalence of gestational diabetes is increasing
and comprises approximately 5% of the pregnant
women. Given the worldwide rising incidence of dia-
betes, as a consequence of changed life style and conse-
quent obesity, improvement of obstetric care for diabetic
patients is essential [13,14]. Moreover, it has been shown
that children born macrosomic are at risk for developing
obesity and diabetes mellitus type 2 at a young age
[15-17]. Reduction of macrosomia will not only reduce
the risk of perinatal complications but may also prevent
these future health problems.
Methods/design
Aims
This trial evaluates the clinical effectiveness, costs and
cost-effectiveness of CGMS use with the aim to optimize
glycaemic control and pregnancy outcome of diabetic
pregnancies relative to standard control methods. The
primary outcome measure is macrosomia. Secondary
obstetric outcome measures are birth weight, neonatal
and maternal morbidity. Furthermore, diabetic outcome
measures are HbA1c level, and glucose variability. In
addition, cost-effectiveness will also be evaluated.
Study design
The study will be a multicentre randomised controlled trial
comparing standard care to standard care with additional
CGMS use. The study will be open, as it is impossible to
blind the pregnant women and health care workers
involved for the strategy to which the women are allocated.
This trial is performed by the Dutch Obstetric Consortium,
a collaboration of the majority of hospitals in the Nether-
lands. It supplies research nurses and online services,
and is supported by the Dutch Society of Obstetrics
and Gynaecology. Approximately 25 hospitals, including
university hospitals, teaching hospitals and non-teaching
hospitals will participate in this trial.
The study has been approved by the ethics committee
of the Academic Medical Centre Amsterdam (reference
number 10/322 # 11.17.0554) and in addition by the
boards of management of all participating hospitals.
Participants
Pregnant women with pre-existing diabetes mellitus (type
1 or 2) before gestational age of 16 weeks or with gesta-
tional diabetes requiring insulin therapy before 30 weeks
gestational age will be asked to participate. Inclusion
criteria include maternal age of at least 18 years and need
for insulin treatment by means of injections or insulin
pump. Patients with severe medical or psychological
comorbidity will be excluded. Multiple pregnancies will
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obstetric evaluation.Recruitment and randomisation
Potential study candidates will be identified by their gy-
naecologist or internist. Patients eligible for participation
in the study will be invited for additional counselling by
a research nurse, to ensure that they will be fully
informed on the nature of the study by means of both
oral and written information. Patients who agree to par-
ticipate will be asked to sign a written informed consent
of which they will receive a copy.
After providing informed consent for the participation in
the study, the patient will be randomly allocated to either
standard care or standard care and additional CGMS use.
Randomisation will be done on a 1:1 basis over the inter-
net, stratified for type of diabetes, using a web-based pro-
gram. The current inclusion status is being displayed on
the GlucoMOMS trial website http://www.studies-obsgyn.
nl/glucomoms/page.asp?page_id=1027Hypothesis
The CGMS has been shown to potentially improve gly-
caemic control as defined by HbA1c levels. Since obstet-
ric complications in diabetic pregnancies, especially
macrosomia, seem to be related to glycaemic control, we
hypothesise that the additional use of CGMS will reduce
the macrosomia rate by 30 percent.Intervention
The continuous glucose monitoring system (CGMS) is a
new technique that is efficacious in the monitoring of
diabetic women. It can provide a comprehensive glucose
profile over a 5–7 days period. The CGMS (CGMS Med-
tronic: Minimed, Northridge,CA) measures glucose
levels through electro-chemical detection in the extracel-
lular fluid of the abdominal subcutaneous tissue and
stores values in a range of 2.2 - 22.2 mmol/L every
10 sec. An average value is stored in the monitor every
5 minutes, providing up to 288 blood glucose measure-
ments (12x24) a day. The subjects are unaware of the
results of the sensor measurements during monitoring
and need to continue self-monitoring of blood glucose
while carrying the monitor. After 5–7 days glucose
profiles are obtained from the monitor and can be
evaluated by the diabetologist and dietary or insulin
therapy changes can be advised.
All study participants will determine their glycaemic
control by self-monitoring of blood glucose levels (4–8
times/day) and HbA1c-levels (every 4 weeks) throughout
the course of pregnancy. Figure 1 represents a flowchart
of the study.Outcome measures
Main study parameter/endpoint
Outcome measures of the trial are related to obstetric
complications and glycaemic control. Macrosomia is the
most frequent complication of diabetes during preg-
nancy and is associated with neonatal morbidity and
long term effects. Therefore, the primary outcome meas-
ure is macrosomia rate. Macrosomia is defined as a birth
weight above the 90th centile.
Secondary maternal endpoints are: pre-eclampsia
(defined as systolic blood pressure ≥ 140 mmHg or diastolic
blood pressure ≥ 90 mmHg occurring after 20 weeks of ges-
tation and simultaneous proteinuria of ≥300 mg/24 hours)
caesarean section, hypoglycemia (subdivided as biochemical
hypoglycemia (self-measured blood glucose < 3.9 mmol/l)
or symptomatic hypoglycemia (symptoms of hypoglycemia
confirmed by self-measured blood glucose < 3.9 mmol/l) or
severe hypoglycemia, (prompting the need for help by
another person)), HbA1c levels throughout the course of
pregnancy, glucose variability (Mean Absolute Glucose
change per patient per hour) and relative glucose variability
(Coefficient of Variability) [18].
Secondary neonatal endpoints are: birth weight, pre-
term birth, perinatal death, birth trauma (including shoul-
derdystocia, clavicle fracture or Erb’s palsy), neonatal
hypoglycemia (defined as blood glucose < 2.6 mmol/l),
respiratory distress syndrome (RDS), broncho pulmonal
dysplasia (BPD), intraventricular haemorrhage II B or
worse, necrotizing enterocolitis (NEC), and sepsis.
Follow up
Long term follow up of the offspring is desirable as long
term effects of diabetic pregnancy on infants, in particu-
lar those born macrosomic, have become evident. Long
term follow up is planned but will depend on future
funding.
Economic evaluation / cost analysis
With two or three continuous glucose monitors (hard-
ware), costing about €1,500 each, the total monitor costs
are €37,500 per centre. We will use 5 sensors (each €50)
per pregnancy, resulting in sensor costs of €37,500,
bringing total equipment costs at €75,000. The
additional costs of CGMS per year (per pregnancy) are
€500. With these crude estimates, a hypothesized 33%
reduction in macrosomia rate, would imply for the short
term a cost-effectiveness ratio of €1,500 per prevented
case of macrosomia, €6,076 per prevented caesarean sec-
tion, €15,189 per prevented case of preterm birth, and
€48,605 per prevented case of neonatal death. A strong
reduction of macrosomia would also reduce downstream
resource use and associated costs of neonatal complica-
tions. The question is to what extent downstream
economic benefits also offset the costs required to obtain
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to-benefit ratio justifies a standard policy of using CGMS
during pregnancy [19,20].
Rising health care costs and reimbursement of expensive
medical devices are not justified unless extensive cost-
effective analysis turns out favourable. Therefore, besides
evaluation of the effectiveness of CGMS on pregnancy
outcome, resource utilization and costs for maternal and
neonatal care will be analysed as well.Statistics
Sample size
We anticipate that a reduction of macrosomia from 45%
to 30% will outweigh the costs of the additional use of
the CGMS. As we assume 10% protocol violations
and drop out, we need to randomise 300 women
(Alpha-error .05, Beta-error .20, one-sided test) of
which 150 will receive additional CGMS use and 150
will be controls.Data analysis
Data will initially be analysed according to the intention
to treat method. The main outcome variable, macroso-
mia, will be assessed by calculating rates in the two
groups, relative risks and 95% confidence intervals as
well as numbers needed to treat. The secondary out-
come measures will be addressed in a similar manner.
Continuous outcome measures will be compared using
parametric and non-parametric tests, depending on the
distribution of the data. We plan a subgroup analysis
of women with diabetes type 1 and type 2 diabetes
and gestational diabetes.Interim analysis
An interim analysis will be performed after the inclusion
of 150 women. This analysis will be done by an inde-
pendent data and safety monitoring committee, which
will not be aware of the allocation of sensor or routine
control when they judge data on effectiveness. In case of
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vise to stop the study. Furthermore, each SAE will be
reported to the data and safety monitoring committee.
Discussion
Women with diabetes in pregnancy are at high risk for
unfavourable pregnancy outcomes. Strict glycaemic con-
trol is required during pregnancy to minimize complica-
tions. After its introduction, continuous glucose
monitoring has gained ground quickly in diabetes care
in order to optimize glycaemic control. However, the
clinical and cost-effectiveness of CGMS to improve
pregnancy outcome remains to be clarified. This ran-
domised controlled trial aims to evaluate the effect
of CGMS use on pregnancy outcome in diabetic
pregnancies.
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